公开(公告)号：US11904139B2

公开(公告)日：2024-02-20

申请号：US17222570

申请日：2021-04-05

Applicant: Medtronic MiniMed, Inc.

Inventor： Benyamin Grosman ,  Louis J. Lintereur ,  Anirban Roy ,  Neha J. Parikh ,  Di Wu ,  Patrick E. Weydt ,  David Dunleavy ,  Ali Dianaty

IPC: A61M5/172

CPC classification number: A61M5/1723 ,  A61M2205/52 ,  A61M2230/201

Abstract: A processor-implemented method for closed-loop control in steady-state conditions includes determining, based on data including historical bolus information but excluding historical basal information, an amount of unmetabolized therapeutic substance in a patient; determining, based on a difference between a most recent measurement of a physiological condition of the patient and a target value for the physiological condition, a first amount or rate of a basal dosage for delivery to the patient; adjusting, based on the amount of unmetabolized therapeutic substance, the first amount or rate of the basal dosage to determine a second amount or rate of the basal dosage; and causing delivery of the second amount or rate of the basal dosage based on communicating the second amount or rate in a delivery command.

公开(公告)号：US11551812B2

公开(公告)日：2023-01-10

申请号：US17004951

申请日：2020-08-27

Applicant: Medtronic MiniMed, Inc.

Inventor： Patrick E. Weydt ,  Pratik J. Agrawal ,  Louis J. Lintereur ,  Lavie Golenberg ,  David Dunleavy

IPC: G16H40/67 ,  G16H20/17 ,  G06F3/01 ,  H04W4/02 ,  A61B5/145 ,  A61B5/00 ,  A61M5/142 ,  G16H40/20 ,  G16H70/40 ,  A61K38/28 ,  A61M5/172 ,  G16H20/60 ,  G06N3/08

Abstract: An example system for therapy delivery includes one or more processors configured to in response to a prediction indicating that the meal event is to occur, output instructions to an insulin delivery device to deliver a partial therapy dosage, to a device to notify the patient to use the insulin delivery device to take the partial therapy dosage, or to the insulin delivery device to prepare the partial therapy dosage prior to the meal event occurring, and in response to a determination indicating that the meal event is occurring (e.g., based on movement characteristics of a patient arm), output instructions to the insulin delivery device to deliver a remaining therapy dosage, to the device to notify the patient to use the insulin delivery device to take the remaining therapy dosage, or to the insulin delivery device to prepare the remaining therapy dosage.

公开(公告)号：US20210338932A1

公开(公告)日：2021-11-04

申请号：US17373502

申请日：2021-07-12

Applicant: Medtronic MiniMed, Inc.

Inventor： Louis J. Lintereur ,  Alexander S. Campbell ,  Taly G. Engel ,  David Dunleavy ,  Benyamin Grosman ,  Anirban Roy

IPC: A61M5/172 ,  G16H20/17

Abstract: A system includes one or more processors and one or more processor-readable storage media storing instructions which, when executed by the one or more processors, cause performance of receiving, via a user interface, confirmation input that indicates user acceptance of a blood glucose (BG) measurement generated by a BG meter device, in response to receiving the confirmation input, using the BG measurement for performing both glucose sensor calibration and bolus calculation, and causing delivery of a bolus based on outputting a delivery command in accordance with the bolus calculation.

公开(公告)号：US20240226434A1

公开(公告)日：2024-07-11

申请号：US18415379

申请日：2024-01-17

Applicant: Medtronic MiniMed, Inc.

Inventor： Benyamin Grosman ,  Louis J. Lintereur ,  Anirban Roy ,  Neha J. Parikh ,  Di Wu ,  Patrick E. Weydt ,  David Dunleavy ,  Ali Dianaty

IPC: A61M5/172

CPC classification number: A61M5/1723 ,  A61M2205/52 ,  A61M2230/201

Abstract: Techniques disclosed herein relate to closed-loop control in steady-state conditions. In some embodiments, the techniques may involve determining an amount of unmetabolized therapeutic substance in a patient; determining, based on a measurement of a physiological condition of the patient and a target value for the physiological condition, a first amount or rate of a basal dosage for delivery to the patient; adjusting, based on the amount of unmetabolized therapeutic substance, the first amount or rate of the basal dosage to determine a second amount or rate of the basal dosage; and causing delivery of the second amount or rate of the basal dosage based on communicating the second amount or rate in a delivery command.

公开(公告)号：US11839744B2

公开(公告)日：2023-12-12

申请号：US17179070

申请日：2021-02-18

Applicant: Medtronic MiniMed, Inc.

Inventor： Benyamin Grosman ,  Louis J. Lintereur ,  Anirban Roy ,  Neha J. Parikh ,  Di Wu ,  Patrick E. Weydt ,  David Dunleavy ,  Ali Dianaty

IPC: A61M5/172

CPC classification number: A61M5/1723 ,  A61M2205/52 ,  A61M2230/201

Abstract: Techniques related to automatically generating a super bolus may include determining an amount of an augmented meal bolus to be delivered to a patient for regulating the patient's glycemic response to a meal. The amount of the augmented meal bolus may exceed a sufficient amount for counteracting a glucose level increase caused by the meal. In some embodiments, the techniques may further include determining a duration of a postprandial reduction period during which basal dosage deliveries to the patient are to be reduced. In some other embodiments, the techniques may further include delivering the augmented meal bolus to the patient prior to determining whether or not to cause reduction of basal dosage deliveries. More specifically, a glucose level of the patient may be obtained after delivery of the augmented meal bolus, and the obtained glucose level may be used to determine whether to reduce basal dosage deliveries.

公开(公告)号：US11744946B2

公开(公告)日：2023-09-05

申请号：US17179109

申请日：2021-02-18

Applicant: Medtronic MiniMed, Inc.

Inventor： Benyamin Grosman ,  Louis J. Lintereur ,  Anirban Roy ,  Neha J. Parikh ,  Di Wu ,  Patrick E. Weydt ,  David Dunleavy ,  Ali Dianaty

IPC: A61M5/172

CPC classification number: A61M5/1723 ,  A61M2205/52 ,  A61M2230/201

Abstract: Techniques related to automatically generating a super bolus may include determining an amount of an augmented meal bolus to be delivered to a patient for regulating the patient's glycemic response to a meal. The amount of the augmented meal bolus may exceed a sufficient amount for counteracting a glucose level increase caused by the meal. In some embodiments, the techniques may further include determining a duration of a postprandial reduction period during which basal dosage deliveries to the patient are to be reduced. In some other embodiments, the techniques may further include delivering the augmented meal bolus to the patient prior to determining whether or not to cause reduction of basal dosage deliveries. More specifically, a glucose level of the patient may be obtained after delivery of the augmented meal bolus, and the obtained glucose level may be used to determine whether to reduce basal dosage deliveries.

公开(公告)号：US11710562B2

公开(公告)日：2023-07-25

申请号：US17004969

申请日：2020-08-27

Applicant: Medtronic MiniMed, Inc.

Inventor： Patrick E. Weydt ,  Pratik J. Agrawal ,  Louis J. Lintereur ,  Lavie Golenberg ,  David Dunleavy

IPC: G16H40/67 ,  G16H20/17 ,  G06F3/01 ,  H04W4/02 ,  A61B5/145 ,  A61B5/00 ,  A61M5/142 ,  G16H40/20 ,  G16H70/40 ,  A61K38/28 ,  A61M5/172 ,  G16H20/60 ,  G06N3/08

CPC classification number: G16H40/67 ,  A61B5/14532 ,  A61B5/7405 ,  A61B5/746 ,  A61K38/28 ,  A61M5/14244 ,  A61M5/14248 ,  A61M5/1723 ,  G06F3/017 ,  G06N3/08 ,  G16H20/17 ,  G16H20/60 ,  G16H40/20 ,  G16H70/40 ,  H04W4/027 ,  A61M2205/3584 ,  A61M2205/502 ,  A61M2205/505 ,  A61M2205/52 ,  A61M2205/581 ,  A61M2205/582 ,  A61M2205/583 ,  A61M2205/8206 ,  A61M2230/201 ,  A61M2230/63

Abstract: Devices, systems, and techniques for controlling delivery of therapy for diabetes are described. In one example, a system includes a wearable device configured to generate user activity data associated with an arm of a user; and one or more processors configured to: identify at least one gesture indicative of utilization of an injection device for preparation of an insulin injection based on the user activity data; based on the at least one identified gesture, generate information indicative of at least one of an amount or type of insulin dosage in the insulin injection by the injection device; compare the generated information to a criteria of a proper insulin injection; and output information indicative of whether the criteria is satisfied based on the comparison.

公开(公告)号：US20220313908A1

公开(公告)日：2022-10-06

申请号：US17222570

申请日：2021-04-05

Applicant: Medtronic MiniMed, Inc.

Inventor： Benyamin Grosman ,  Louis J. Lintereur ,  Anirban Roy ,  Neha J. Parikh ,  Di Wu ,  Patrick E. Weydt ,  David Dunleavy ,  Ali Dianaty

IPC: A61M5/172

Abstract: A processor-implemented method for closed-loop control in steady-state conditions includes determining, based on data including historical bolus information but excluding historical basal information, an amount of unmetabolized therapeutic substance in a patient; determining, based on a difference between a most recent measurement of a physiological condition of the patient and a target value for the physiological condition, a first amount or rate of a basal dosage for delivery to the patient; adjusting, based on the amount of unmetabolized therapeutic substance, the first amount or rate of the basal dosage to determine a second amount or rate of the basal dosage; and causing delivery of the second amount or rate of the basal dosage based on communicating the second amount or rate in a delivery command.

公开(公告)号：US20220257859A1

公开(公告)日：2022-08-18

申请号：US17179109

申请日：2021-02-18

Applicant: Medtronic MiniMed, Inc.

Inventor： Benyamin Grosman ,  Louis J. Lintereur ,  Anirban Roy ,  Neha J. Parikh ,  Di Wu ,  Patrick E. Weydt ,  David Dunleavy ,  Ali Dianaty

IPC: A61M5/172

Abstract: Techniques related to automatically generating a super bolus may include determining an amount of an augmented meal bolus to be delivered to a patient for regulating the patient's glycemic response to a meal. The amount of the augmented meal bolus may exceed a sufficient amount for counteracting a glucose level increase caused by the meal. In some embodiments, the techniques may further include determining a duration of a postprandial reduction period during which basal dosage deliveries to the patient are to be reduced. In some other embodiments, the techniques may further include delivering the augmented meal bolus to the patient prior to determining whether or not to cause reduction of basal dosage deliveries. More specifically, a glucose level of the patient may be obtained after delivery of the augmented meal bolus, and the obtained glucose level may be used to determine whether to reduce basal dosage deliveries.